JLE

Journal de Pharmacie Clinique

MENU

Optimization of melphalan therapeutic scheme : in vitro study on human cancer cell lines Volume 18, issue 1, Mars 1999

Figures

See all figures

Authors

Melphalan was investigated for its antitumoral activity using two schedules of exposition (massive versus repeated administration) in two human cancer cell lines (8226 and A2780). Repeated administration of melphalan was more effective than massive administration of the same total dose. The IC50 values averaged 8,2 and 0,16 mug/ml for 8226 cells (myeloma), and 7,5 and 0,53 mug/ml for A2780 cells (ovarian, carcinoma), after massive and repeated administration, respectively (p < 0,001). In conclusion, this in vitro study allows to think that repeated infusion of melphalan could be more effective than massive administration.